Article Text

PDF
A7.5 A whole blood micro-RNA signature for primary SjÖgren’s syndrome-related lymphoma
  1. J Tarn1,
  2. S Cockell2,
  3. C Gillespie3,
  4. S Al-Ali1,4,
  5. K James1,5,
  6. J Locke1,
  7. S Bowman6,
  8. B Griffiths7,
  9. D Young1,
  10. WF Ng1,7
  1. 1Musculoskeletal Research Group, Newcastle University, Newcastle Upon Tyne
  2. 2Bioinformatics Support Unit, Newcastle University, Newcastle Upon Tyne
  3. 3School of Mathematics and Statistics, Newcastle University, Newcastle Upon Tyne
  4. 4Department of Biology, College of Science, University of Basrah, Iraq
  5. 5School of Computing Science, Newcastle University, Newcastle Upon Tyne
  6. 6University Hospital Birmingham, Birmingham
  7. 7Freeman Hospital, Newcastle Upon Tyne

Abstract

Background/Purpose Micro RNAs (miRNAs) are 18–25 nt non-coding RNAs that bind target/complementary sequences within the 3’UTR of RNA molecules steering them towards degradation or translational repression, and play a key role in the regulation of gene expression. Better understanding of the expression pattern of miRNAs in diseases may improve our understanding of the biological basis of the disease and identify potential biomarkers. The role of miRNAs in primary Sjögren’s syndrome (PSS) and PSS-related lymphoma remains poorly understood. The aim of this project is to identify a miRNA signature for PSS-related lymphoma.

Methods We profiled the expression of miRNAs in whole blood (PaxGene) total RNA preparations using the Exiqon miRCURY LNA array which encompasses >1400 miRNAs and other small non-coding RNAs. A discovery cohort comprised of 36 samples from the United Kingdom Primary Sjögren’s Syndrome Registry (UKPSSR) (12 PSS patients with lymphoma, 12 PSS patients without lymphoma, 12 healthy controls) were used in the initial analysis. We also explored different normalisation strategies and developed an approach, which we considered most appropriate for analysing these data. Real-Time PCR was used to validate the most highly differentially expressed miRNAs between groups. A miRNA signature for PSS-related lymphoma was identified using cluster analysis followed by validation with a second independent cohort of 36 patients and controls.

Results The initial miRNA array profiling revealed a clear clustering of the 3 subject groups. Between patient groups with and without lymphoma association, 44 miRNAs were differentially expressed. RT-PCR was used to validate 3 out of 9 of the most highly differentially expressed miRNAs. A 5-miRNA signature for pSS-associated lymphoma was identified using clustering analysis followed by validation with a second independent cohort of 36 patients and controls. The sensitivity and specificity of the signature is excellent with an area under the ROC curve of 0.92.

Conclusion We have identified 5 miRNAs that are differentially expressed in peripheral blood between PSS patients with lymphoma and those without lymphoma. Identifying the mRNA targets of these miRNAs in PSS may improve our understanding of the pathogenesis of PSS-related lymphoma. Furthermore, miRNAs may be useful biomarkers for PSS-related lymphoma.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.